Physical approaches for nucleic acid delivery to liver.
The liver is a key organ for numerous metabolic pathways and involves many inherited diseases that, although being different in their pathology, are often caused by lack or overproduction of a critical gene product in the diseased cells. In principle, a straightforward method to fix such problem is to introduce into these cells with a gene-coding sequence to provide the missing gene product or with the nucleic acid sequence to inhibit production of the excessive gene product. Practically, however, success of nucleic acid-based pharmaceutics is dependent on the availability of a method capable of delivering nucleic acid sequence in the form of DNA or RNA to liver cells. In this review, we will summarize the progress toward the development of physical methods for nucleic acid delivery to the liver. Emphasis is placed on the mechanism of action, pros, and cons of each method developed so far. We hope the information provided will encourage new endeavor to improve the current methodologies or develop new strategies that will lead to safe and effective delivery of nucleic acids to the liver.
Kamimura
Kenya
K
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, 527 Salk Hall, Pittsburgh, PA 15261, USA.
Liu
Dexi
D
D004247:DNA / Q000008:administration & dosage* / Q000627:therapeutic use; D018274:Electroporation; D017353:Gene Deletion; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007267:Injections; D008099:Liver / Q000187:drug effects / Q000502:physiology*; D008107:Liver Diseases / Q000235:genetics* / Q000628:therapy*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D012313:RNA / Q000008:administration & dosage* / Q000627:therapeutic use; D012449:Safety; D017384:Sequence Deletion
D004364:Pharmaceutical Preparations; D012313:RNA; D004247:DNA